Spend an hour in any PCOS community and inositol will come up more than every prescription medication combined. It is sold in supermarkets, it is the centrepiece of a great many PCOS supplement brands, and the marketing around it is confident in a way that the research is not.
So it is worth reading what the actual evidence review concluded, because the gap between the two is the whole story.
What the guideline found
The 2023 update of the international PCOS guideline commissioned a systematic review and meta-analysis specifically on inositol — pooling the trials of inositol alone and in combination, across hormonal features, clinical features, weight and reproductive outcomes.
The conclusion it reached, in the guideline’s own framing: inositol offers limited clinical benefit in PCOS, and where a medication is being considered for metabolic features, metformin has greater demonstrated efficacy.
That is not “it does nothing” and it is not “it is dangerous”. It is something more specific and less satisfying: the trials that exist are not strong enough, or consistent enough, to support the claims routinely made for it.
Why the research is weaker than the marketing
A few features of this literature explain the mismatch, and they generalise to most supplement evidence you will meet:
The studies are small. Many have a few dozen participants. A small trial can produce a striking result by chance, and striking results are the ones that get quoted.
They measure different things. Some report hormone levels, some report cycle regularity, some report ovulation, some report weight. When trials measure different outcomes, pooling them gets harder and the pooled answer gets vaguer.
Formulations vary. Myo-inositol, D-chiro-inositol, and combinations of the two in various ratios are not interchangeable, and trials have used all of them. “Inositol works” is a claim about a category containing several different interventions.
Follow-up is short. PCOS is lifelong. A twelve-week trial cannot tell you much about a condition measured in decades.
None of that means the substance is useless. It means the honest state of knowledge is uncertain, and uncertainty is the one thing a supplement label never says.
What this page will not tell you
A dose. We do not publish them, for any substance, including the ones sold without a prescription. A dose is treatment advice, and it belongs to someone who knows what else you take and what your kidneys are doing — interactions with prescribed medication are the specific reason “it’s just a supplement” is a bad reason to skip the conversation.
Whether you should take it. That is a decision for you and a clinician, and it depends on things this page cannot know.
What this page can tell you is what to expect from the evidence, so the decision is made with the real numbers rather than the ones on the packet.
The question worth asking instead
If you are considering it, the useful question is not “does inositol work?” — the answer is a shrug with citations. It is:
What would I expect to change, how would I know, and by when?
That question is answerable, and it is answerable by you. If you decide, with your doctor, to try something, then the way to find out whether it did anything is to have a record of the months before and the months after: cycle start dates, how often each symptom actually turned up, what your labs said and when.
Without that, three months later you have an impression, and impressions are shaped by what you paid and what you hoped. With it, you have two numbers to compare.
That is also, incidentally, the honest reason a supplement can appear to work: cycles vary, symptoms come and go, and something started during a bad stretch will usually be followed by a better one. The only thing that distinguishes an effect from a return to your own average is a record that goes back far enough to know what your average is.
Where the guideline says more
Inositol is one of many supplements marketed for PCOS, and the pattern above repeats for most of them: small trials, mixed outcomes, and a conclusion of insufficient evidence. The guideline covers them together and is consistently more cautious than any product page you will find.
If you want the primary source rather than a summary of it, the guideline is published openly, and the inositol review it commissioned is a separate paper. Reading the abstract of either takes about four minutes and is more informative than any amount of forum consensus.